Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 07, 2011 09:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Present at 13th Annual BIO CEO and Investor Conference

BUFFALO, NY--(Marketwire - February 7, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 13th Annual BIO CEO and Investor Conference,...
January 25, 2011 09:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Receives $1.6 Million Development Contract From Defense Threat Reduction Agency of Department of Defense for CBLB502

BUFFALO, NY--(Marketwire - January 25, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it received a $1,589,106 development contract from the Defense Threat Reduction Agency...
January 20, 2011 09:37 ET | Source: Cleveland Biolabs

Cleveland BioLabs Announces Potential Direct Anticancer Effect of CBLB502

BUFFALO, NY--(Marketwire - January 20, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has accumulated preclinical data demonstrating that CBLB502, a drug under development to...
January 04, 2011 09:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Present at Sidoti Microcap Conference

BUFFALO, NY--(Marketwire - January 4, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Sidoti Microcap Conference, January 10, in New...
December 23, 2010 16:50 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Raise Approximately $8.39 Million in Registered Direct Offering With Single Institutional Investor

BUFFALO, NY--(Marketwire - December 23, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has agreed to sell 1,400,000 shares of its common stock at a price of $5.99 per share in...
November 30, 2010 11:25 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs' CBLB502 Granted Orphan Drug Status From FDA for Prevention of Death Following a Potentially Lethal Dose of Total Body Irradiation During or After a Radiation Disaster

BUFFALO, NY--(Marketwire - November 30, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that CBLB502, a drug under development to treat exposure to radiation, has been granted Orphan...
November 02, 2010 09:40 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs and Incuron Receive $489,000 in Qualifying Therapeutic Discovery Project Grants

BUFFALO, NY--(Marketwire - November 2, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company and Incuron, LLC, a joint venture between the Company and Bioprocess...
November 01, 2010 10:11 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Start of Phase IB Trial for Prototype Curaxin CBLC102 in Russia

BUFFALO, NY--(Marketwire - November 1, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures,...
October 19, 2010 09:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Receives Notice of Patent Allowance From China for CBLB502

BUFFALO, NY--(Marketwire - October 19, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that it has received a notice of grant of patent for CBLB502 from the State Intellectual...
October 14, 2010 09:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Present at NewsMakers in the Biotech Industry Conference

BUFFALO, NY--(Marketwire - October 14, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 17th Annual NewsMakers in the Biotech...